NCT03609294View on ClinicalTrials.gov

A Clinical Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Fimasartan and Linagliptin in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

July 18, 2018

Primary Completion Date

March 4, 2019

Study Completion Date

June 30, 2019

Conditions
HypertensionDiabetes
Interventions
DRUG

Treatment A (Fimasartan, Linagliptin)

Co-administration of Fimasartan and Linagliptin

DRUG

Treatment B (Fimasartan/Linagliptin)

Fixed Dose Combination of Fimasartan 120 mg/Linagliptin 5 mg

Trial Locations (1)

03080

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Boryung Pharmaceutical Co., Ltd

INDUSTRY